Identification

Summary

Terpin hydrate is an expectorant used to treat bronchitis, pneumonia, bronchiectasis, COPD, and infectious or inflammatory diseases of the upper respiratory tract.

Generic Name
Terpin hydrate
DrugBank Accession Number
DB13163
Background

Terpin hydrate is an expectorant, commonly used to loosen mucus and ease congestion in patients presenting with acute or chronic bronchitis, and related pulmonary conditions. It is derived from sources such as turpentine, oregano, thyme and eucalyptus. It was popular in the United States since the late nineteenth century, but was removed from marketed medications in the 1990s after FDA stated that "based on evidence currently available, there are inadequate data to establish general recognition of the safety and effectiveness of these ingredients". Elixirs of terpin hydrate are still available to patients as prescription medications to be prepared by specialty compounding pharmacies.

Type
Small Molecule
Groups
Approved, Experimental
Structure
Weight
Average: 190.283
Monoisotopic: 190.156894568
Chemical Formula
C10H22O3
Synonyms
  • cis-p-methane-1,8-diol monohydrate
  • cis-terpin hydrate
  • Terpin cis-form hydrate
  • Terpin hydrate
  • Terpin monohydrate
  • Terpinene hydrate
  • Terpinol hydrate
External IDs
  • AI3-01762

Pharmacology

Indication

Terpin hydrate is used in the treatment of acute and chronic bronchitis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease, infectious and inflammatory diseases of the upper respiratory tract.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

It acts to facilitate the removal of mucus from the respiratory tract. It prevents the exacerbation of excessive mucus production and secretion due to airway bacterial or viral infections, asthma or chronic bronchitis. Expectorants like terpin hydrate change mucus consistency and make coughing more productive.

Mechanism of action

Terpin hydrate improves mucociliary function by working directly on the bronchial secretory cells in the lower respiratory tract to liquify and facilitate the elimination of bronchial secretionsas well as exerting a weak antiseptic effect on the pulmonary parenchyma. It is thought to increase the amount of fluid in the respiratory tract, which increases the flow and clearance of local irritants and as well as reducing the viscosity of mucus 2.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Overdose can cause nausea, vomiting and abdominal pain.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Pastilles ValdaTerpin hydrate (.016 mg) + Eucalyptol (.451 mg) + Guaiacol (.016 mg) + Levomenthol (3.28 mg) + Thymol (.016 mg)LozengeOralLabs Valda1981-12-311997-08-01Canada flag
Terpin Hydrate Codeine Elx CFTerpin hydrate (1.83 %) + Codeine (.23 %)ElixirOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1965-12-311997-08-08Canada flag
UDECOF TABLETTerpin hydrate (85 mg) + Dextromethorphan hydrobromide (20 mg) + Guaifenesin (50 mg)Tablet, coatedOralบริษัท สหการโอสถ (1996) จำกัด จำกัด2009-04-09Not applicableThailand flag
Valda PastillesTerpin hydrate (.016 mg / loz) + Eucalyptol (.451 mg / loz) + Guaiacol (.016 mg / loz) + Levomenthol (3.28 mg / loz) + Thymol (.016 mg / loz)LozengeOralBayer Inc Consumer Care1995-12-312007-08-02Canada flag
Valda Pastilles Lemon FlavouredTerpin hydrate (.016 mg / loz) + Eucalyptol (.451 mg / loz) + Guaiacol (.016 mg / loz) + Levomenthol (3.28 mg / loz) + Thymol (.016 mg / loz)LozengeOralLabs Valda1992-12-311996-09-10Canada flag
กลัยคอฟTerpin hydrate (130 mg) + Dextromethorphan hydrobromide (15 mg) + Guaifenesin (100 mg)Tablet, coatedOralบริษัท เจริญเภสัชแล็บ จำกัด2017-08-05Not applicableThailand flag
คูซี่Terpin hydrate (125 MG) + Chlorpheniramine (2 MG)Tabletบริษัท วี แอนด์ พี ลาบอราตอรี่ จำกัด จำกัด1993-05-27Not applicableThailand flag
ซินฟุซซี่Terpin hydrate (125 MG) + Chlorpheniramine (2 MG)Tabletบริษัท ห้างขายยาตราเจ็ดดาว จำกัด1993-05-272020-09-29Thailand flag
ซี.พี.เอ็ม.-2 เอ็กซ์เพ็คท์Terpin hydrate (125 MG) + Chlorpheniramine (2 MG)Tabletบริษัท เมดิซีน โปรดักส์ จำกัด1993-05-27Not applicableThailand flag
ดี - โค้ทTerpin hydrate (85 mg) + Dextromethorphan hydrobromide (20 mg) + Guaifenesin (50 mg)Tablet, coatedOralบริษัท บี.เอ็ล.ฮั้ว จำกัด จำกัด1986-11-14Not applicableThailand flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as menthane monoterpenoids. These are monoterpenoids with a structure based on the o-, m-, or p-menthane backbone. P-menthane consists of the cyclohexane ring with a methyl group and a (2-methyl)-propyl group at the 1 and 4 ring position, respectively. The o- and m- menthanes are much rarer, and presumably arise by alkyl migration of p-menthanes.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Monoterpenoids
Direct Parent
Menthane monoterpenoids
Alternative Parents
Monocyclic monoterpenoids / Cyclohexanols / Tertiary alcohols / Cyclic alcohols and derivatives / Organic oxides / Hydrocarbon derivatives
Substituents
Alcohol / Aliphatic homomonocyclic compound / Cyclic alcohol / Cyclohexanol / Hydrocarbon derivative / Monocyclic monoterpenoid / Organic oxide / Organic oxygen compound / Organooxygen compound / P-menthane monoterpenoid
Molecular Framework
Aliphatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
S3V868548T
CAS number
2451-01-6
InChI Key
JGKJMBOJWVAMIJ-OFAZAQPOSA-N
InChI
InChI=1S/C10H20O2.H2O/c1-9(2,11)8-4-6-10(3,12)7-5-8;/h8,11-12H,4-7H2,1-3H3;1H2/t8-,10+;
IUPAC Name
(1s,4s)-4-(2-hydroxypropan-2-yl)-1-methylcyclohexan-1-ol hydrate
SMILES
O.CC(C)(O)[C@H]1CC[C@@](C)(O)CC1

References

General References
  1. Seagrave J, Albrecht HH, Hill DB, Rogers DF, Solomon G: Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells. Respir Res. 2012 Oct 31;13:98. doi: 10.1186/1465-9921-13-98. [Article]
  2. 12. (2011). In Applied Pharmacology (pp. 129). Elsevier Health Sciences. [ISBN:978-1-4377-0310-8]
PubChem Compound
17141
PubChem Substance
347829270
ChemSpider
16736914
RxNav
89916
Wikipedia
Terpin
MSDS
Download (79.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral
LozengeOral
ElixirOral
Tablet, coatedOral
Tablet
Tablet, sugar coatedOral
Capsule
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)116MSDS
water solubilityPartially soluble in cold waterMSDS
logP2.320ChemIDplus
Predicted Properties
PropertyValueSource
Water Solubility8.31 mg/mLALOGPS
logP1.85ALOGPS
logP1.19ChemAxon
logS-1.3ALOGPS
pKa (Strongest Acidic)18.93ChemAxon
pKa (Strongest Basic)-0.69ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area40.46 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity49.37 m3·mol-1ChemAxon
Polarizability20.11 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at January 07, 2017 03:12 / Updated at May 27, 2021 02:58